RT Journal Article
SR Electronic
T1 Rifaximin does not increase the rate of 30-day mortality in patients with cirrhosis and daptomycin in two National US-based cohorts
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.06.24318164
DO 10.1101/2024.12.06.24318164
A1 Silvey, Scott
A1 Patel, Nilang
A1 Khoruts, Alexander
A1 Bajaj, Jasmohan S
YR 2024
UL http://medrxiv.org/content/early/2024/12/08/2024.12.06.24318164.abstract
AB Recently, a higher rate of resistance to daptomycin in patients exposed to rifaximin has been shown. However, since laboratory resistance patterns found in silico or ex vivo do not account for the complex pharmacokinetic, pharmacodynamic, microbial, and host-related factors in patients, the clinical impact of rifaximin on resistance to daptomycin needs clarification. Although rifaximin is commonly used for irritable bowel syndrome and traveler’s diarrhea, the main reason for long-term use is hepatic encephalopathy (HE) in cirrhosis. Here we show that 30-day outcomes (transplant or mortality) in two large US-based cohorts (Veterans Affairs Corporate Data Warehouse and TriNetX database) in daptomycin users on rifaximin were not different compared to those without daptomycin. with or without pre-existing rifaximin use.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Richmond Veterans Affairs IRB and Virginia Commonwealth University IRBI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors